Latest news : Valeo Pharma Inc.

25-02-04	Xediton Pharmaceuticals Inc. completed the acquisition of Valeo Pharma Inc. (OTCPK:VPHI.F).	CI
25-01-16	Xediton Pharmaceuticals Inc. entered into a definitive agreement to acquire Valeo Pharma Inc. (OTCPK:VPHI.F).	CI
24-01-28	Valeo Pharma Inc. Auditor Raises 'Going Concern' Doubt	CI

More news

Press Releases: Valeo Pharma Inc.

07-10	WEPP Relief Available In RVO Context, Commercial List Finds For The First Time In Ontario	AQ
25-02-06	Valeo Pharma announces the closing of a share purchase agreement with Xediton Pharmaceuticals Inc.	AQ
22-01-05	VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION	PR
21-11-03	Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta	PR
21-10-13	Valeo Pharma : C O R R E C T I O N from Source -- Valeo Pharma inc./	PR

More press releases

Managers and Directors: Valeo Pharma Inc.

Manager	Title	Age	Since
Pascal Tougas DFI	Director of Finance/CFO	-	2023-11-19
Nelly Komari CTO	Chief Tech/Sci/R&D Officer	-	2021-05-31
Frédéric Dumais IRC	Investor Relations Contact	-	2019-05-31

Director	Title	Age	Since
Steven Saviuk CHM	Chairman	67	2024-08-05
Richard MacKay CHM	Chairman	91	2018-07-24
Marc Léger BRD	Director/Board Member	67	2022-04-26

More insiders

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed OTC Markets Other stock markets 10:42:53 2026-07-15 EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-99.00%

Market Cap	6.24M 4.43M 3.89M 3.62M 3.33M 423M 6.35M 42.92M 16.8M 210M 16.62M 16.26M 725M	P/E 2022	-2.09x	P/E 2023	-0.45x
Enterprise Value	64.5M 45.77M 40.17M 37.41M 34.41M 4.37B 65.6M 444M 174M 2.17B 172M 168M 7.49B	EV / Sales 2022	3.37x	EV / Sales 2023	1.35x
Free-Float	52.66%	Yield 2022 *	-	Yield 2023	-

Current year	0		0
1 year	0		0
3 years	0		0.4
5 years	0		0.84
10 years	0		1.4

Date	Insider	Type	Main position	% Market Cap.
11/11/24	Frédéric Dumais	Other	Investor Relations Manager	0%
11/11/24	Frédéric Dumais	Other	Investor Relations Manager	0%
11/11/24	Frédéric Dumais	Other	Investor Relations Manager	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALEO PHARMA INC.	0.00%	0.00%	-	-	98
ELI LILLY AND COMPANY	+0.07%	+4.48%	+59.26%	+167.32%	1,089B
JOHNSON & JOHNSON	+0.27%	+4.50%	+58.91%	+59.46%	643B
ABBVIE INC.	+1.12%	+4.86%	+38.91%	+77.58%	465B
ROCHE HOLDING AG	-1.10%	+9.51%	+40.27%	+34.52%	359B
NOVARTIS AG	-0.75%	+3.53%	+36.99%	+42.48%	303B
ASTRAZENECA PLC	+1.52%	+3.23%	+17.51%	+17.22%	267B
NOVO NORDISK A/S	+0.44%	+5.38%	-2.94%	-38.34%	226B
AMGEN INC.	+0.16%	+7.65%	+29.81%	+68.29%	212B
GILEAD SCIENCES, INC.	-0.56%	+2.06%	+16.45%	+74.70%	167B
Average	+0.10%	+4.57%	+32.80%	+55.91%	373.11B
Weighted average by Cap.	+0.14%	+5.14%	+42.68%	+81.63%

Valeo Pharma Inc. Stock

Stocks

VPHIF

CA91915B1085

Pharmaceuticals

Valuation: Valeo Pharma Inc.

Chart: Valeo Pharma Inc.

Latest news : Valeo Pharma Inc.

Press Releases: Valeo Pharma Inc.

Course Extremes

Managers and Directors: Valeo Pharma Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

	2022	2023
Net sales	27.74M 19.69M 17.28M 16.09M 14.8M 1.88B 28.22M 191M 74.72M 933M 73.92M 72.33M 3.22B	53.91M 38.26M 33.58M 31.27M 28.76M 3.66B 54.83M 371M 145M 1.81B 144M 141M 6.26B
Net income	-25.75M -18.27M -16.04M -14.93M -13.73M -1.75B -26.19M -177M -69.34M -866M -68.6M -67.11M -2.99B	-27.81M -19.74M -17.32M -16.13M -14.83M -1.89B -28.28M -191M -74.89M -935M -74.09M -72.49M -3.23B
Net Debt	38.94M 27.64M 24.25M 22.58M 20.77M 2.64B 39.61M 268M 105M 1.31B 104M 102M 4.52B	58.26M 41.35M 36.29M 33.79M 31.08M 3.95B 59.26M 401M 157M 1.96B 155M 152M 6.77B